In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Reevaluating Clinical Trial Design

October 20, 2017

Reevaluating Clinical Trial Design

Clinical trials to evaluate new drugs are typically built around one design, the randomized controlled trial, but this method has come under scrutiny in recent years for being expensive, lengthy, and cumbersome. In this podcast you'll hear from experts asking if alternative designs would be better for determining the safety and efficacy of new therapies.

This podcast was produced following a conference on this topic held in partnership between the NYU School of Medicine and the Academy. It was made possible with support from Johnson & Johnson.